Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

862 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. Naing A, et al. Among authors: chen hx. Clin Cancer Res. 2011 Sep 15;17(18):6052-60. doi: 10.1158/1078-0432.CCR-10-2979. Epub 2011 Jul 12. Clin Cancer Res. 2011. PMID: 21750201 Free PMC article. Clinical Trial.
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M, Chen HX. Saltz LB, et al. Among authors: chen hx. J Clin Oncol. 2007 Oct 10;25(29):4557-61. doi: 10.1200/JCO.2007.12.0949. Epub 2007 Sep 17. J Clin Oncol. 2007. PMID: 17876013 Clinical Trial.
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Azad NS, et al. Among authors: chen hx. J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. J Clin Oncol. 2008. PMID: 18669456 Free PMC article. Clinical Trial.
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. Rini BI, et al. Among authors: chen hx. Clin Cancer Res. 2009 Oct 1;15(19):6277-83. doi: 10.1158/1078-0432.CCR-09-0717. Epub 2009 Sep 22. Clin Cancer Res. 2009. PMID: 19773375 Free PMC article. Clinical Trial.
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.
Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, Chen HX, Krailo MD, Adamson PC, Blaney SM. Malempati S, et al. Among authors: chen hx. J Clin Oncol. 2012 Jan 20;30(3):256-62. doi: 10.1200/JCO.2011.37.4355. Epub 2011 Dec 19. J Clin Oncol. 2012. PMID: 22184397 Free PMC article. Clinical Trial.
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Naing A, et al. Among authors: chen hx. Clin Cancer Res. 2012 May 1;18(9):2625-31. doi: 10.1158/1078-0432.CCR-12-0061. Epub 2012 Mar 31. Clin Cancer Res. 2012. PMID: 22465830 Free PMC article. Clinical Trial.
862 results